AMED Quote, Financials, Valuation and Earnings

Chemed has a net margin of 10.26% compared to Amedisys's net margin of 11.09%. Amedisys's return on equity of 7.55% beat Chemed's return on equity of 26.04%.

Amedisys has a consensus price target of $97.38, signalling downside risk potential of -0.72%. On the other hand Chemed has an analysts' consensus of $677.33 which suggests that it could grow by 22.59%. Given that Chemed has higher upside potential than Amedisys, analysts believe Chemed is more attractive than Amedisys.

Amedisys has a beta of 0.940, which suggesting that the stock is 5.975% less volatile than S&P 500. In comparison Chemed has a beta of 0.543, suggesting its less volatile than the S&P 500 by 45.694%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chemed offers a yield of 0.36% to investors and pays a quarterly dividend of $0.50 per share. Amedisys pays -- of its earnings as a dividend. Chemed pays out 8.97% of its earnings as a dividend. Chemed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amedisys quarterly revenues are $594.8M, which are smaller than Chemed quarterly revenues of $646.9M. Amedisys's net income of $61M is lower than Chemed's net income of $71.8M. Notably, Amedisys's price-to-earnings ratio is 36.19x while Chemed's PE ratio is 26.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.37x versus 3.34x for Chemed. Usually stocks with elevated PS ratios are considered overvalued.

Health Catalyst has a net margin of 10.26% compared to Amedisys's net margin of -29.9%. Amedisys's return on equity of 7.55% beat Health Catalyst's return on equity of -20.06%.

Amedisys has a consensus price target of $97.38, signalling downside risk potential of -0.72%. On the other hand Health Catalyst has an analysts' consensus of $7.45 which suggests that it could grow by 97.73%. Given that Health Catalyst has higher upside potential than Amedisys, analysts believe Health Catalyst is more attractive than Amedisys.

Amedisys has a beta of 0.940, which suggesting that the stock is 5.975% less volatile than S&P 500. In comparison Health Catalyst has a beta of 1.526, suggesting its more volatile than the S&P 500 by 52.646%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Health Catalyst offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. Health Catalyst pays out -- of its earnings as a dividend.

Amedisys quarterly revenues are $594.8M, which are larger than Health Catalyst quarterly revenues of $79.4M. Amedisys's net income of $61M is higher than Health Catalyst's net income of -$23.7M. Notably, Amedisys's price-to-earnings ratio is 36.19x while Health Catalyst's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.37x versus 0.76x for Health Catalyst. Usually stocks with elevated PS ratios are considered overvalued.

Option Care Health has a net margin of 10.26% compared to Amedisys's net margin of 3.51%. Amedisys's return on equity of 7.55% beat Option Care Health's return on equity of 15.22%.

Amedisys has a consensus price target of $97.38, signalling downside risk potential of -0.72%. On the other hand Option Care Health has an analysts' consensus of $38.56 which suggests that it could grow by 21.28%. Given that Option Care Health has higher upside potential than Amedisys, analysts believe Option Care Health is more attractive than Amedisys.

Amedisys has a beta of 0.940, which suggesting that the stock is 5.975% less volatile than S&P 500. In comparison Option Care Health has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.903%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Option Care Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. Option Care Health pays out -- of its earnings as a dividend.

Amedisys quarterly revenues are $594.8M, which are smaller than Option Care Health quarterly revenues of $1.3B. Amedisys's net income of $61M is higher than Option Care Health's net income of $46.7M. Notably, Amedisys's price-to-earnings ratio is 36.19x while Option Care Health's PE ratio is 25.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.37x versus 1.05x for Option Care Health. Usually stocks with elevated PS ratios are considered overvalued.

OptimizeRx has a net margin of 10.26% compared to Amedisys's net margin of -10.03%. Amedisys's return on equity of 7.55% beat OptimizeRx's return on equity of -13.03%.

Amedisys has a consensus price target of $97.38, signalling downside risk potential of -0.72%. On the other hand OptimizeRx has an analysts' consensus of $15.67 which suggests that it could grow by 18.69%. Given that OptimizeRx has higher upside potential than Amedisys, analysts believe OptimizeRx is more attractive than Amedisys.

Amedisys has a beta of 0.940, which suggesting that the stock is 5.975% less volatile than S&P 500. In comparison OptimizeRx has a beta of 1.337, suggesting its more volatile than the S&P 500 by 33.676%.

Amedisys has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OptimizeRx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amedisys pays -- of its earnings as a dividend. OptimizeRx pays out -- of its earnings as a dividend.

Amedisys quarterly revenues are $594.8M, which are larger than OptimizeRx quarterly revenues of $21.9M. Amedisys's net income of $61M is higher than OptimizeRx's net income of -$2.2M. Notably, Amedisys's price-to-earnings ratio is 36.19x while OptimizeRx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amedisys is 1.37x versus 2.57x for OptimizeRx. Usually stocks with elevated PS ratios are considered overvalued.